ropeginterferon alfa-2b + P1801

**Ropeginterferon alfa-2b + P1801** is an investigational combination therapy for cancer, specifically viral oncogene-induced tumors and other malignancies. Ropeginterferon alfa-2b is a long-acting mono-pegylated type I interferon that acts via the interferon-alpha/beta receptor, activating the JAK/STAT signaling pathway and exerting antiviral and antitumor effects. P1801 is a novel monoclonal antibody targeting PD-1, designed to block PD-1-mediated immunosuppression and enhance antitumor immune responses. P1801 has demonstrated unique binding properties compared to established PD-1 inhibitors (pembrolizumab, nivolumab) and induces IL-2 secretion from activated T cells. The combination is under investigation for synergistic immunotherapy in oncology, and an early-phase clinical trial is planned for advanced solid tumors[1][2][3].

Other names

ropeginterferon alfa-2b-njftpegylated proline interferon alpha-2b